Basal Insulin Tresiba Approved for Teens and Kids as Young as One

Novo Nordisk recently announced FDA approval of an expanded pediatric indication for Tresiba, meaning that the basal insulin can now be used to treat people with type 1 and type 2 diabetes as young as age one. The label update is based on data from the BEGIN YOUNG 1 trial, which showed Tresiba is safe and effective when used in children with type 1 diabetes.

Read more

Posted in Glucose & Insulin